The invention relates to a composition for use in the treatment of metabolic oxidative alterations in non-alcoholic steatohepatitis (NASH), wherein said composition comprises silybin and wherein the treatment is administered to patients having an altered lipidomic profile. Patients having altered lipidomic profile show an high TBARS value in TBARS test (lipid peroxidation marker) with respect to healthy subjects.